Malignant pleural effusion from prostate adenocarcinoma

James C. Knight a, *, Malia A. Ray b, Sadia Benzaquena a

a University of Cincinnati, Pulmonary, Critical Care, and Sleep Division, 231 Albert Sabin Way, ML 0564, Cincinnati, OH 45267-0564, USA
b Mercy Medical Associates, 2055 Hospital Drive, Suite 200, Batavia, OH 45103, USA

Keywords:
Pleural effusion
Malignancy
Prostate adenocarcinoma
Pleural metastasis

Abstract
Prostate adenocarcinoma is the most common newly diagnosed cancer in males. Pulmonary and pleural metastasis are not uncommon on autopsy, but malignant effusions are not common clinical findings. There are no current recommendations to guide prostate specific antigen level assessment in pleural fluid.

A 73 yo w/prostate cancer presented with complaints of subacute worsening of exertional dyspnea. He underwent a CT of the chest which excluded pulmonary emboli but did show moderate to large bilateral pleural effusions.

The patient had a thoracentesis performed which confirmed an exudative effusion with atypical cells and elevated PSA levels. Metastatic visceral & parietal foci of prostate adenocarcinoma were found on medical pleuroscopy. The patient was symptomatically treated with bilateral tunneled chest tube catheters for intermittent drainage.

Pulmonary metastasis secondary to prostate cancer is commonly found on autopsy, with pulmonary metastasis in 46% of patients and pleural metastasis in 21% of patients. Pleural effusions are not common, in one series, only 6/620 (1%) were found to have pleural masses/nodules or effusions. Diagnosis of pleural effusion secondary to metastatic prostate cancer can be achieved by direct cytology evaluation and/or PSA level elevation in the fluid. While specific, the sensitivity is not high enough to rule out disease if negative. Elevated pleural fluid PSA levels may aid in the diagnosis; however, there are no current recommendations as to what level may be considered diagnostic. Further studies are needed to define the sensitivity and specificity of PSA in pleural fluid.

Introduction
A patient with metastatic prostate adenocarcinoma presented with subacute dyspnea and significant bilateral pleural effusions. The effusion was exudative with atypical cells and elevated prostate specific antigen (PSA) levels. Metastatic visceral & parietal foci of prostate adenocarcinoma were found on medical pleuroscopy. The patient was symptomatically treated with tunneled chest tube catheters for drainage.

Case report
A 73-year-old former smoker with medical castration-resistant metastatic prostate cancer, currently on Abiraterone, presented with complaints of subacute worsening of exertional dyspnea. He

underwent a CT of the chest with contrast which excluded pulmonary emboli but did show moderate to large bilateral pleural effusions.

A left sided thoracentesis revealed an exudative effusion with a total protein of 28 g/L (2.8 g/dL) and a serum to pleural fluid protein ratio of 0.57. The LDH, cholesterol, and glucose were within transudative range. Cell count showed 460 nucleated cells w/atypical cells that stained weakly positive for CEA. The PSA level in the pleural fluid was 1619 µg/L (ng/mL), the serum level was 2540 µg/L (ng/mL).

Removal of two liters of pleural fluid resulted in symptomatic improvement. The patient returned seven days later for recurrent dyspnea. A right sided thoracentesis was performed which resulted in improvement of symptoms. The pleural fluid PSA level was 1936 µg/L (ng/mL).

Given the rapid reoccurrence with symptomatic improvement after drainage, evaluation for pleurodesis was recommended. A medical pleuroscopy was performed which showed severely inflamed, nodular parietal and visceral pleurae with lung

* Corresponding author. Tel.: +1 318 801 4794; fax: +1 513 558 4858.
E-mail address: jamesknightl64@yahoo.com (J.C. Knight).
Diagnosis of pleural effusion secondary to metastatic prostate cancer can be achieved by cytologic examination with immunostaining for PSA. While specific, the sensitivity is not high enough to rule out disease if negative [9]. Cascinu et al. evaluated tumor markers in malignant pleural effusions and found PSA elevated in all effusions caused by prostate adenocarcinoma [10]. There has been at least one transudative pleural effusion caused by prostate adenocarcinoma diagnosed by elevated pleural PSA levels [11]. There is also a case report of prostate cancer diagnosed via malignant effusion without known disease elsewhere [12].

In summary, malignant effusions from prostate adenocarcinoma remain a rare clinical finding. Conventional cytology may miss the diagnosis. Elevated pleural fluid PSA levels can aid in the diagnosis. There are no current recommendations as to what level may be considered diagnostic. Our case and other reports support the finding that pleural fluid PSA levels are markedly elevated in malignant effusions secondary to prostate cancer. Further studies are needed to define the sensitivity and specificity of PSA in pleural fluid at a certain diagnostic threshold.

Acknowledgments

All authors listed have contributed sufficiently to the project to be included as authors, and all those who are qualified to be authors are listed in the author byline. To the best of our knowledge, no conflict of interest, financial or other, exists. All authors have reviewed and approved the manuscript. The manuscript has not been previously published and is not under consideration in the same or substantially similar form in any other peer-reviewed media. Institution work was performed: University of Cincinnati Medical Center. Acknowledgment to Ikjot Bhutani MD for pathology assistance.

References

[1] Gittes RF. Carcinoma of the prostate. N Engl J Med 1991;324:236–45.
[2] American Cancer Society. Cancer facts & figures 2001. New York, NY: American Cancer Society; 2001.
[3] Catalona WJ, Scott WW. Carcinoma of the prostate (vol 2). In: Harrison JH, Gittes RF, Perlmutter AD, Stamey TA, Walsh PC, editors. Campbell's urology. 4th ed. Philadelphia: WB Saunders; 1979. p. 1085.
[4] Tan W, Buskirk S. Histologically diagnosed lung metastasis from prostate cancer: diagnosis, clinical course and response to treatment (abstr). ASCO 2005: American Society of Clinical Oncology. Alexandria, VA: ASCO; 2005 [abstract no. 309].
[5] Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31(5):578–83.
[6] Long MA, Husband JE. Features of unusual metastases from prostate cancer. Br J Radiol 1999;72:933–41.
[7] Vinjamoori AH, Jagannathan JP, Shinagare A, Taglini M, Oh W, Van den Abbeele A, et al. Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR 2012;199:367–72.
[8] Apple JS, Paulson D, Baber C, Putman C. Advanced prostate carcinoma: pulmonary manifestations. Radiology 1985;154:601–4.
[9] Renshaw A, Nappi D, Gibas E. Cytology of metastatic adenocarcinoma of the prostate in pleural effusions. Diagn Cytopathol 1995;15(2):101–7.
[10] Cascinu S, Del Ferro E, Barbanti I, Ligi M, Fedeli A, Catalano G. Markers in the diagnosis of malignant serous effusions. Am J Clin Oncol 1997;20:247–50.
[11] Fujisawa N, Sugawara H, Yabe H, Iishi A, Matsubayashi H, Watanabe T, et al. Value of prostate-specific antigen elevated in transudative pleural effusion for diagnosis of prostate cancer-induced paramalignant pleural effusion. J Med Cases 2013;4(7):507–10.
[12] Brown G, Ginsberg P, Harkaway R. Prostate adenocarcinoma diagnosed by prostate-specific antigen analysis of pleural fluid. Urol Int 1998;60:197–8.